Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors
Tyrosine kinase inhibitors (TKIs) improved overall survival (OS) in patients with chronic myeloid leukemia in chronic phase (CML‑CP).
A prospective analysis of 483 patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML‑CP) treated with tyrosine kinase inhibitors (TKIs) compared overall survival (OS) to that of matched general population. Five‑year OS was 96 % (80 % for age 65–84 years) and relative OS was 94 % (88 % at 10 years). Achievement of complete cytogenetic response (CCyR) or better was associated with relative survival comparable to the general population. The study suggests that with TKI therapy, patients with CML‑CP enjoy near‑normal life expectancy.
The finding confirms that TKIs substantially extend survival in CML‑CP and that the relative survival approaches that of the general population, underscoring the effectiveness of current standard therapy.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025
- Chronic myeloid leukemia: Current guidelines for diagnosis and management
- Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment‑free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co‑primary endpoint
- Information about Project 4: Chronic myeloid leukemia (CML)
- Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia